The myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies with relatively heterogeneous spectrums of presentation. The major clinical problems in these disorders are morbidities caused by patients' cytopenias and the potential for MDS to evolve into acute myeloid leukemia (AML). Managing MDS is complicated by the generally advanced age of the patients (median ages range from 65–70 years), the attendant non-hematologic comorbidities, and older patients' relative inability to tolerate certain intensive forms of therapy. In addition, when the illness progresses into AML, these patients experience lower response rates to standard therapy than patients with de novo AML.
For the most recent version of the guidelines, please visit NCCN.org
If the inline PDF is not rendering correctly, you can download the PDF file here.
Since 1898, Roswell Park Cancer Institute (RPCI), America's first cancer center, has forged an exemplary reputation based on the combined strength of its basic/translational research, multidisciplinary oncology teams, educational programs, and compassionate staff. A seamless interface of scientific inquiry and clinical application, and an aggressive clinical trials program, afford patients access to promising breakthroughs in cancer diagnostics, technology, and treatments.
Since 1998, 60% of RPCI's 25-acre campus has undergone major renovation and expansion. A world-class Center for Genetics and Pharmacology will open in spring 2006.
RPCI ranks among the nation's top 1% of cancer centers and teaching hospitals for patient satisfaction with physician services and overall care.
David C. Hohn, MD (second photo on cover), joined Roswell Park Cancer Institute as President and CEO in January of 1997. Dr. Hohn oversees operations of the hospital, research facilities, and the education department. Dr. Hohn also serves as Chairman of the Board for the National Comprehensive Cancer Network.